Who are Fuzheng Huayu tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Yangxinshi tablet simulants, Twice Normal-dose Wenxin Granules, Jinlida granules, Gastrodia and Uncaria Drink, Qishenyiqi dripping pills, Shensong Yangxin capsule.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fuzheng-huayu-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Fuzheng Huayu tablet — Competitive Intelligence Brief

Fuzheng Huayu tablet (Fuzheng Huayu tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Traditional Chinese medicine herbal formulation. Area: Hepatology.

marketed Traditional Chinese medicine herbal formulation Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Fuzheng Huayu tablet (Fuzheng Huayu tablet) — ShuGuang Hospital. Fuzheng Huayu tablet is a traditional Chinese medicine formulation that promotes liver fibrosis reversal and hepatic function recovery through anti-inflammatory and antifibrotic pathways.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Fuzheng Huayu tablet TARGET	Fuzheng Huayu tablet	ShuGuang Hospital	marketed	Traditional Chinese medicine herbal formulation
Yangxinshi tablet simulants	Yangxinshi tablet simulants	Dongzhimen Hospital, Beijing	marketed	Traditional Chinese medicine herbal formulation
Twice Normal-dose Wenxin Granules	Twice Normal-dose Wenxin Granules	China Academy of Chinese Medical Sciences	marketed	Traditional Chinese medicine herbal formulation
Jinlida granules	Jinlida granules	Shanghai Jiao Tong University School of Medicine	marketed	Traditional Chinese medicine herbal formulation
Gastrodia and Uncaria Drink	Gastrodia and Uncaria Drink	Shanghai Institute of Hypertension	marketed	Traditional Chinese medicine herbal formulation
Qishenyiqi dripping pills	Qishenyiqi dripping pills	Qilu Hospital of Shandong University	marketed	Traditional Chinese medicine herbal formulation
Shensong Yangxin capsule	Shensong Yangxin capsule	kejiang Cao	marketed	Traditional Chinese medicine herbal formulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Traditional Chinese medicine herbal formulation class)

Beijing Bozhiyin T&S Co., Ltd. · 1 drug in this class
China Academy of Chinese Medical Sciences · 1 drug in this class
Dongzhimen Hospital, Beijing · 1 drug in this class
Jinling Hospital, China · 1 drug in this class
Liaoning University of Traditional Chinese Medicine · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
Qilu Hospital of Shandong University · 1 drug in this class
Shanghai Institute of Hypertension · 1 drug in this class
Shanghai Jiao Tong University School of Medicine · 1 drug in this class
Shanghai Municipal Hospital of Traditional Chinese Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fuzheng Huayu tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/fuzheng-huayu-tablet. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab